Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Starbloom Capital is a venture capital firm founded by James Fickel in 2021. The firm operates from its offices in New York and San Francisco. Starbloom Capital focuses on investing in breakthrough innovations in deep technology, particularly in the fields of longevity biotechnology, neuroscience, and artificial intelligence.
Since its inception, Starbloom Capital has built a portfolio of seven companies, showcasing its commitment to advancing the frontiers of science and technology. The firm is closely associated with the Amaranth Foundation, which emphasizes longevity and neuroscience research and philanthropy. This connection enhances Starbloom's mission to support visionary founders who are developing impactful solutions in these critical sectors.
As of now, Starbloom Capital has not disclosed its total assets under management (AUM) or fund sizes, but its active investment strategy indicates a strong presence in the venture capital landscape.
Starbloom Capital invests primarily in deep tech innovations, with a strong emphasis on sectors such as biotech, artificial intelligence, and longevity. The firm targets early-stage investments, specifically in the seed and Series A stages, allowing it to partner closely with founders at critical points in their development.
The firm seeks to collaborate with visionary founders who are pushing the boundaries of science and technology. Starbloom Capital looks for companies that are developing impactful solutions in longevity biotechnology, neuroAI, and emerging industries. The firm values innovative approaches that can lead to significant advancements in healthcare and technology.
Geographically, Starbloom Capital maintains a global focus, with particular attention to opportunities in North America. The firm’s investment strategy is designed to support companies that are not only pioneering new technologies but also addressing pressing challenges in health and longevity.
Starbloom Capital's portfolio includes a diverse range of companies that are making significant strides in their respective fields. Notable portfolio companies include:
This portfolio reflects Starbloom Capital's commitment to supporting innovative companies that are at the forefront of biotechnology and deep tech advancements.
James Fickel: Founder and Managing Director of Starbloom Capital, James has a background in venture capital and deep technology investments.
Kevin Liang: Chief Operating Officer, Kevin brings operational expertise and experience in managing venture capital firms.
Jarod Rutledge: Director of Biotech Investments, Jarod specializes in identifying and supporting biotech innovations.
Joanne Peng: Director of NeuroAI Investments, Joanne focuses on investments in artificial intelligence and neuroscience.
Patrick Mineault: Director of NeuroAI Research, Patrick leads research initiatives in neuroAI technologies.
Emilio Aguilar Rosenthal: Manager of Data Science & Analytics, Emilio supports portfolio companies with data-driven insights and analytics.
To pitch Starbloom Capital, founders should send an email to hello@starbloom.capital. It is recommended to include a concise pitch deck that outlines the business model, market opportunity, and team qualifications. Founders should expect a response within a few weeks, depending on the volume of inquiries.
Warm introductions are preferred but not mandatory. A clear and compelling presentation of the startup's vision and potential impact will enhance the chances of engagement.
As of April 2026, Starbloom Capital has been actively investing in innovative companies within the biotech and AI sectors. The firm participated in a $23 million Series A round for Bexorg, which focuses on neuroscience drug discovery.
Starbloom Capital continues to expand its portfolio, with a total of seven companies currently under its management. The firm remains committed to supporting breakthroughs in longevity and deep technology.
What criteria does Starbloom Capital use for investments?
Starbloom Capital primarily invests in early-stage companies within the biotech, AI, and longevity sectors. The firm looks for visionary founders who are pushing the boundaries of science and technology.
How can founders pitch to Starbloom Capital?
Founders can reach out to Starbloom Capital via email at hello@starbloom.capital. It is advisable to include a detailed pitch deck outlining the business model, market opportunity, and team background.
What makes Starbloom Capital different from other VC firms?
Starbloom Capital distinguishes itself through its focus on deep tech innovations and its strong ties to the Amaranth Foundation, which enhances its commitment to longevity and neuroscience.
What is the geographic scope of Starbloom Capital's investments?
The firm has a global investment focus, with a particular emphasis on opportunities in North America.
What kind of support do portfolio companies receive?
Starbloom Capital provides strategic guidance, access to a network of industry experts, and support in navigating the complexities of deep tech and biotech sectors.
What is the typical check size for investments?
Specific check sizes have not been disclosed, but the firm participates in seed and Series A rounds, indicating a range that aligns with early-stage funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.